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To date, CML has an annual frequency of 1-2 
new cases per 100,000 adults, and accounts 
for 15% of the total incidence of leukemia. 
Globally, the average age at diagnosis is 
between 45 and 55 years, while in Italy it’s 
60 years [3].
The natural history of the disease can be clas-
sified into three main and progressive phases: 
the chronic phase (CP), in which the disease 
is less aggressive and has a variable duration 
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Chronic Myeloid Leukemia (CML) is a clo-
nal disorder characterized by a genetic defect 
of the hematopoietic stem cells, which causes 
the proliferation and progressive accumula-
tion of granulocyte cells in the bone marrow 
[1,2]. Granulocyte cells accumulate at first in 
the bone marrow and, at a later stage, in the 
blood and other organs.
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AbstrAct
BACKGROUND: Tyrosine kinase inhibitors (TKI) have dramatically improved survival in chronic myeloid leukemia 
in chronic phase (CML-CP), with a high percentage of patients reaching a major molecular response (MMR). Recently, 
several clinical trials demonstrated that some patients with CML-CP who achieve a sustained MMR on tyrosine kinase 
inhibitor (TKI) therapy can safely discontinue their therapy and attempt treatment-free remission (TFR).
Objective: The aim of the study was to evaluate the clinical and economic impact of TFR in naïve patients with CML-CP 
who start treatment with nilotinib, imatinib or dasatinib as first-line therapy, from the perspective of the Italian National 
Health Service (NHS).
METHODS: An Excel-based budget impact model was developed, in order to estimate the costs of the patients in first-line 
pharmacological treatment with CML. A specific Markov model was built, to simulate seven years of treatment with dif-
ferent TKIs. A systematic literature review was carried out, to identify the epidemiological and economic data, which were 
subsequently used to inform the model. The model considers two scenarios: 1) a Standard of Care (SoC) scenario, with the 
current estimated distribution of patients over the various TKI treatment, versus 2) an innovative scenario, characterized 
by an increase in the use of nilotinib (+28%) and generic imatinib (+35%) and a decrease in the use of dasatinib (-17%). A 
one-way deterministic sensitivity analysis was performed, in order to consider the variability of the results as a function of 
the main parameters considered in the model.
RESULTS: The model estimated that 775 patients with CML-CP could be treated with a TKI as first-line drug. The in-
novative scenario could increase TFR patients by approximately 60% and reduce the costs by more than € 30 million over 
7 years. The increase in the use of nilotinib and the generic imatinib would generate a significant expenditure reduction.
CONCLUSIONS: This study demonstrates the economic effects of discontinuing TKIs in CML-CP patients. The increase 
in the use of nilotinib and the generic imatinib could generate an increase in the number of patients who achieve TFR, as 
well as an actual cost reduction. 
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sibility is being explored of discontinuing tre-
atment in patients who have reached deep and 
stable molecular response levels. This possi-
bility – not even contemplated until a few ye-
ars ago – has now been accepted and official-
ly registered for nilotinib, thanks to the results 
of the ENESTfreedom clinical study [7]. The 
aim of this study was to evaluate the potential 
for TFR (treatment-free remission) following 
frontline nilotinib treatment. After a median 
time of first-line treatment with nilotinib of 
approximately 3 and a half years, more than 
half (51.6%) of the 190 patients who achie-
ved a sustained deep molecular response were 
able to discontinue therapy, while remaining 
in full remission for 48 weeks, the time pe-
riod over which the primary endpoint was 
evaluated. These results are confirmed at lon-
ger follow up with a TFR rate equal to 49% 
at 96 weeks [11]. At present, the possibility of 
discontinuing therapy theoretically exists also 
for patients treated with imatinib and dasati-
nib, but this possibility is not officially regi-
stered for these drugs, nor is it suggested in 
the current guidelines, and therefore it is still 
confined to clinical trials.
When selecting a TKI frontline therapy, seve-
ral factors must be considered: in addition to 
the efficacy and safety profile of each availa-
ble treatment option, treatment cost can be an 
important consideration, particularly with the 
introduction of generic imatinib. The incre-
ased potential for TFR eligibility with nilo-
tinib (and the potential cost-savings through 
treatment discontinuation) may be additional 
factors to consider for some patients when 
selecting a frontline TKI. These long-term 
considerations are increasingly important as 
patients with CML now have a life expec-
tancy comparable to that of the general po-
pulation.
The aims of this analysis are: to evaluate the 
therapeutic pathway of newly diagnosed Phi-
ladelphia chromosome-positive CML (Ph+ 
CML) patients on first-line treatment with 
imatinib (400 mg once daily), nilotinib (300 
mg twice daily), or dasatinib (100 mg once 
daily); to quantify the economic impacts 
generated by TFR following nilotinib in the 
first-line treatment of Ph+ CML patients and 
to estimate the economic sustainability that 
could be obtained from the disinvestment ge-
nerated by the generic imatinib.
Method
In order to calculate the estimated costs of 
CML patients on first-line treatment with TKI 
drugs, an Excel-based Budget Impact model, 
able to simulate the therapeutic pathway of 
the patients undergoing treatment with the 
of 3-5 years; the accelerated phase (AP), a 
short, intermediate phase characterized by a 
different clinical symptomatology; and the 
blast phase (BP) – or crisis –, a stage whe-
re the disease is acute and terminal [3,4]. At 
the time of diagnosis, approximately 85% 
of patients are in the chronic phase, while in 
the remaining 15% a more advanced disease 
phase is already evident [4].
The current treatment of CML involves the 
use of tyrosine kinase inhibitors (TKIs): the-
se greatly improved the survival of patients, 
whose life expectancy – from an average of 
5-7 years at the end of the 1990s – has now 
been increased to over 25 years post-diagno-
sis [5].
Currently, guidelines recommend three drugs 
for the initial management of a newly dia-
gnosed CML-CP patient: imatinib, dasatinib, 
and nilotinib.
Imatinib was the first TKI class drug appro-
ved by the US Food and Drug Administra-
tion for the treatment of CML-CP [3]. In the 
following years, second-generation TKIs 
– dasatinib and nilotinib – were introduced, 
all showing the ability to induce molecular 
and cytogenetic responses in patients who 
had failed therapy with imatinib. Over the 
years, several trials demonstrated the supe-
riority of nilotinib and dasatinib vs imatinib 
in the first-line treatment; these two drugs 
were associated to a higher rate of major mo-
lecular response (MMR) and deep molecular 
responses (MR4.0 and MR4.5), and to a lower 
percentage of progression of the chronic pha-
se to the most advanced disease stages [6-8]. 
In light of these clinical trials, both dasatinib 
and nilotinib were authorized for the first-line 
treatment of CML, and the current European 
Leukemia Net guidelines, published in 2013, 
provide equal recommendations for the use 
of imatinib, dasatinib or nilotinib [9].
In the majority of cases, first-line therapy 
quickly eliminates leukemia cells: generally, 
the clinical picture and the blood count re-
turn to normal (full hematological remission) 
within the first few months of treatment. 
However, this does not imply the total era-
dication of the disease: a large proportion of 
leukemic cells survive, and can be identified 
through more sophisticated analytical me-
thods. Therefore, even after a full hematolo-
gical remission, therapy should be continued 
for years, first of all in order to achieve the 
MMR, and subsequently to allow the patient 
to achieve deep molecular responses (MR4.0 
and MR4.5), so that the progression to the 
advanced stages of the disease can be avoi-
ded as much as possible [10].
Based on recent knowledge, therapy had to 
be continued indefinitely; however, the pos-
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sting of 17 discrete and complementary he-
alth states, is based on the stratification of pa-
tients in different health conditions, modeled 
on the basis of the 33 transition probabilities 
(with six-month cycles) used to populate the 
model. The model and the probabilities used 
to populate the Markov model and to estima-
te the Markovian traits have been discussed 
and validated by clinical experts.
In detail, the model provides for the possi-
bility of initiating treatment with one of the 
drugs considered in the analysis that will pro-
duce, with different probabilities, an MMR, a 
sub-optimal response or a disease progression 
(AP/BC). This section of the model is defi-
ned by one six-month cycle and represents 
the starting therapy phase (start), in which pa-
tients spread over the various disease states. 
If the patient reaches a molecular response, 
he has the potential to achieve a deep mole-
cular response (MR4.5) and maintain it for up 
to 4 years (Markovian tunnel highlighted by 
the blue area). If the deep response persists 
until the fourth year of therapy, there will be 
the possibility (for the therapies that include 
it) to reach the discontinuation of therapy 
(TFR). Once the TFR has been reached, the 
model provides for the possibility of entering 
a persistent discontinuation state, or resuming 
treatment with a deep response. For the MMR 
state and each MR4.5 state, the model provides 
a limited switch chance. If the patient starts 
a disease progression (AP/BC), the chances 
are the treatment switch or the allogeneic 
transplantation. Death due to the disease can 
occur only in advanced stage patients.
Figure 1. Markov model structure
AP/BC = disease progression; MR4.5 = deep molecular response; MMR = major molecular response; 
MR = molecular response; TFR = treatment-free remission
drugs studied (nilotinib, imatinib, dasatinib) 
was developed. For the implementation of 
the model, the guidelines recommended by 
the International Society of Pharmacoecono-
mics and Outcome Research (ISPOR) were 
followed [12,13]. To obtain the parameters 
for the model implementation and the calcu-
lation of the expenditure due to the treatment 
of CML, a systematic review of the literature 
was carried out, by examining publications 
that analyze, describe and compare epide-
miological and/or economic evaluation stu-
dies on the TKIs of interest.
Identification of the population 
eligible for treatment
The first phase of the analysis focused on 
identifying the population eligible for the 
drugs under study, i.e. patients with newly 
diagnosed, not-yet-advanced CML-CP.
In particular, to the population resident in 
Italy in 2016 [14], the rate of incidence of the 
disease was applied (1-2 cases per 100,000 
[3]). The model assumes that, out of the 912 
diagnosed patients, 15% are not eligible for 
treatment, since they have been identified in 
an already advanced stage of the disease [4]. 
Through this method, it is estimated that, in 
Italy, the number of patients annually diagno-
sed and treated with a TKI is 775.
Therapeutic pathways projection
In the second phase, a Markov model was de-
veloped to represent the disease progression 
in patients diagnosed with CML and treated 
with TKIs (Figure 1) [15]. The model, consi-
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Time horizon and 
analysis scenarios
According with the aim of the analysis, the 
model considered a seven-year simulation 
time horizon from the beginning of treatment, 
in order to appreciate the effects of the TFR 
in terms of health and economic impacts. 
This is in line with the ISPOR guidelines 
which state that a time horizon longer than 
a few years «may be needed to illustrate the 
offsetting disease cost-savings from the inter-
vention that may occur in future years» [13].
Two distribution scenarios of the strategies 
analyzed were compared. In particular, in 
the base case, it is assumed that patients are 
distributed by treatment on the basis of what 
indicated in Table II, and that this distribu-
tion represents a realistic approximation of 
the strategies currently adopted in Italy. In 
this scenario, the possibility to reach TFR 
and the use of the generic imatinib is not 
provided for, so that the combined effects of 
the two innovations can be quantified. The 
alternative scenario hypothesizes that the 
disinvestment generated by the switch from 
branded imatinib to generic imatinib, and 
the possibility of an early discontinuation of 
treatment (TFR), allow a gradual increase in 
the number of patients treated with nilotinib 
(+18%, Table II).
Cost parameters
The costs considered in the model refer to 
the direct health costs associated with the 
management of CML-CP patients. As far as 
this type of cost is concerned, the data pu-
blished by Lucioni et al. in 2015 [4] were 
mainly considered. The costs derived from 
the Lucioni study (Table III) [4] have been 
appropriately transformed to be consistent 
with the six-monthly cycles. For the cost of 
the switch, the aggregation of the various 
alternative treatments, in case the patient is 
intolerant or resistant to treatment, was used 
(Appendix A).
statistical analyses
The results were represented as the net dif-
ference between the spending impact of the 
base case versus the spending impact of the 
Patients distribution (%)
Treatment Base case Alternative scenario
Nilotinib 32 50
Imatinib (originator) 46 0
Dasatinib 22 5
Imatinib (generic) 0 45
Total 100 100
Table II. Analysis scenarios
Cost parameters Base case Min Max source
Pharmacological therapy and aT (€)
Cost of therapy 1 year
Nilotinib (year 1) 27,963 [16]
Nilotinib (year 2) 31,958 [16]
Imatinib (originator) 23,205 [17]
Imatinib (generic) 5,105 [18]
Dasatinib (year 1) 37,361 [16]
Dasatinib (year 2) 42,698 [16]
Cost of AT (year 1) 141,493 [4]
Monitoring and follow up (€) 3 months
Costs of monitoring
MMR/MR4.5 203 [4]
MR sub-optimal/intolerance 646 [4]
AP/BC 781 532 1,030 [4]
AT (subsequent years) 52 21 83 [4]
TFR 52 21 83 Assumed to be equal to 
AT (subsequent years)
Other costs (€)
Cost of AEs
Nilotinib 2,343 Attributed to the first year of treatment [4]
Imatinib 2,343 Attributed to the first year of treatment Assumed to be equal to 
nilotinib
Dasatinib 1,736 Attributed to the first year of treatment [4]
Switch cost 4,922 Average cost of second-line treatments1 life 
time attributed to every patient switched
[4]
Cost of death due to disease 7,800 [4]
Table III. Mean annual costs
1 Second-line treatments considered: dasatinib, ponatinib, bosutinib
AE = adverse events; MR4.5 = deep molecular response; MMR = major molecular response; MR = molecular response; AT = allogeneic transplantation; 
TFR = treatment-free remission
These successive phases of the model are re-
presented as annual cycles (Year 1-Year 7).
estimate of the model probabilities
In order to calculate the probabilities of tran-
sition in the first simulation cycle, it was de-
cided to consider the evidence presented in 
the ENESTnd, ENESTFreedom and DASI-
SION clinical studies (Table I). In particular, 
the ENESTnd study [6] enrolled 283 patients 
treated with nilotinib 300 mg twice daily, 281 
patients treated with nilotinib 400 mg twice 
daily and 283 patients treated with imatinib 
400 mg once daily. Observation of these pa-
tients allowed to obtain estimates of the pro-
babilities of response to the treatment and 
progression of the disease for nilotinib and 
imatinib 3 years after the start of treatment. 
The model assumes that the response and/or 
the progression are concentrated in the first 6 
months from the start of therapy (assumption 
related to the time lag of the Markovian mo-
del). In the absence of a direct comparison 
between nilotinib, imatinib and dasatinib, the 
probability of response and progression of 
dasatinib was estimated through the response 
and progression relative risks recorded in the 
DASISION study (head-to-head comparison 
between imatinib and dasatinib) [8], applied 
to the transition probabilities estimated for 
imatinib by the ENESTnd study [6].
TRF estimates were derived from the 
ENESTFreedom study [7] and modeled 
through the support of the expert opinion. For 
the implementation of the model, to the ori-
ginal probabilities appropriate changes and 
adaptations were applied, that can be found 
in Appendix A.
Transition probabilities (%)
MMr Mr4.5 aP/BC Death
eligible 
for TFr
TFr confirmed 
(6 months after)
source
Nilotinib 73.4 31.6 0.7 1.4 88.4 51.6 [6,7]
Imatinib 54.1 17.8 3.5 0.4 52.0 56.0 [6,7]
Dasatinib 68.1 32.8 3.3 1.6 0.0 0.0 [6,8]
Table I. Evidence from the pivotal trials used to estimate the probabilities in the model
AP/BC = disease progression; MR4.5= deep molecular response; MMR = major molecular response; TFR = treatment-free remission
25Farmeconomia. Health economics and therapeutic pathways 2017; 18(1)
F. S. Mennini, A. Marcellusi, R. Viti, G. Saglio
Time horizon and 
analysis scenarios
According with the aim of the analysis, the 
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and the use of the generic imatinib is not 
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alternative scenario hypothesizes that the 
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the possibility of an early discontinuation of 
treatment (TFR), allow a gradual increase in 
the number of patients treated with nilotinib 
(+18%, Table II).
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the direct health costs associated with the 
management of CML-CP patients. As far as 
this type of cost is concerned, the data pu-
blished by Lucioni et al. in 2015 [4] were 
mainly considered. The costs derived from 
the Lucioni study (Table III) [4] have been 
appropriately transformed to be consistent 
with the six-monthly cycles. For the cost of 
the switch, the aggregation of the various 
alternative treatments, in case the patient is 
intolerant or resistant to treatment, was used 
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base case versus the spending impact of the 
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alternative scenario, considering the diffe-
rence both in the annual spending and in the 
cumulative savings over the years.
In order to estimate the impact of the uncer-
tainty of the input parameters on the results 
of the analysis, a one-way sensitivity analysis 
was conducted. In this analysis, some input 
data of the budget impact model were varied 
within an uncertainty range, and the impact 
on the final result was represented by a tor-
nado graph.
In particular, the impact of the variation of 
the following parameters was analyzed:
1. Patients treated with nilotinib over time 
(min: 8% - max: 28%);
2. % of patients in acute chronic phase (min: 
1% - max: 5%);
3. Relative risk (RR) of reaching MMR – 
dasatinib (± 20%);
4. Probability of reaching MMR – nilotinib 
(± 20%);
5. Probability of achieving TFR – nilotinib 
(± 20%);
6. Monitoring cost (min-max as reported in 
Table III);
7. Other direct costs (± 20%).
results
Below are the Budget Impact results in the 
perspective of the Italian National Health 
Service (NHS), over a time horizon from one 
to seven years from the start of treatment.
To date, the epidemiological model estimates 
775 patients eligible for the treatment with 
the drugs in analysis. Table IV shows the 
evolution of patients over the different simu-
lation years and within each Markovian state 
analyzed. The innovative scenario allows for 
a significant slowdown in the disease pro-
gression (-21.5% compared to the base case), 
as well as a lower number of therapeutic 
switches (-3%), and fewer deaths (-12.1%). 
In the alternative scenario, the number of pa-
tients in treatment who discontinue therapy 
without restarting is equal to 187.
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number of patients who can achieve the TFR. 
Figure 3 shows the evolution of the budget 
impact in cumulative terms. In particular, it 
is to be noted that the innovative strategy al-
lows for a spending reduction at 4 years of 
approximately € 29 million, reaching over € 
54 million at 7 years (30% and 36% of the to-
tal expenditure over 7 years in the base case, 
respectively).
Finally, a one-way deterministic sensitivity 
analysis was performed, in which the spen-
ding differential between the two scenarios is 
Figure 2. Results of the budget impact a) per year and b) at year 7: base case vs alternative scenario. Nilotinib: + 18%, imatinib 
(originator): -46% , dasatinib: -17%, imatinib (generic): +35%
Figure 3. Results of the cumulative budget impact a) per year and b) at year 7: base case vs alternative scenario. Nilotinib: + 18%, 
imatinib (originator): -46% , dasatinib: -17%, imatinib (generic): +35%
Figure 4. One-way sensitivity analysis at a) year 4 and b) at year 7 (million €)
As a result of the effects on the health of the 
population, Figure 2 shows how the alterna-
tive scenario allows for an initial spending 
reduction of € 8.3 million in the first year, 
mainly due to the disinvestment generated by 
generic drugs. These annual spending reduc-
tions decrease to € 4.6 million in the third year 
of the analysis, rising again from the fourth 
year onwards, until reaching a spending re-
duction of over € 9.4 million in the seventh 
year of the analysis. In this case, the spending 
decrease is largely attributable to the greater 
Patients distribution (n.)
Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7
Base case
Treatment 488 485 482 479 476 474 471
Switch 268 271 274 277 280 282 285
Progression 7 6 6 5 5 4 4
Death 12 13 14 14 15 15 15
TFR 0 0 0 0 0 0 0
Total 775 775 775 775 775 775 775
alternative scenario
Treatment 496 493 491 372 353 323 294
Switch 262 265 268 271 273 275 277
Progression 5 5 4 4 4 3 3
Death 11 12 12 13 13 13 14
TFR 0 0 0 116 132 160 187
Total 775 775 775 775 775 775 775
Table IV. Patient distribution per analysis scenario and disease state
TFR = treatment-free remission
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In all simulated scenarios, the innovative sce-
nario always allows for a reduction in spen-
ding, versus an increase in nilotinib-treated 
patients. The main parameters that affect bud-
get results are: a) the probability of reaching 
MMR with nilotinib; b) the probability of 
reported, based on each modified parameter 
(Figure 4). The origin of the chart axis corre-
sponds to the original differential of  € 28.9 
million at 4 years (Figure 4a) and € 54.5 mil-
lion at 7 years (Figure 4b).
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tal expenditure over 7 years in the base case, 
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Finally, a one-way deterministic sensitivity 
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of the TFR of over € 1.2 million at 4 years 
and € 10.5 million in the seventh year of the 
analysis, which is to be added to the effects 
generated by the spending reduction ensured 
by the patent expiration date of imatinib.
This work, like all the economic model, has 
various limits, that we attempted to control. 
First, the model was constructed by combi-
ning data from multiple randomized clini-
cal trials that had homogeneous populations 
within the study, but heterogeneous ones 
among the studies considered. To date, the 
lack of sufficient information to provide an 
adequate meta-analysis and the inability to 
have appropriate comparative data did not 
allow for achieving better estimates. Howe-
ver, all clinical information and modeling as-
sumptions have been validated and discussed 
with Key Opinion Leaders, who have identi-
fied adequate uncertainty parameters, which 
were then used to construct the deterministic 
sensitivity analysis.
Finally, it should be specified that in the model 
it was simulated that patients who fail therapy 
continue to remain within the model until the 
end of the 7 years of analysis, and at a constant 
therapy cost, estimated by national literature. 
This assumption is a methodological limit, 
which however has a little impact on the final 
estimates, since it represents a cost item con-
stant for both the scenarios considered.
In conclusion, this paper verified the sustai-
nability of the treatment with nilotinib com-
pared to the main treatments currently used 
(dasatinib and imatinib originators). It has 
also been shown that the possibility to rele-
ase resources by introducing the generic ver-
sion of imatinib, in support of the nilotinib 
treatment, could be an effective strategy to 
generate additional savings and improve the 
patients’ quality of life. Our study is a first 
attempt in Italy to quantify the potential cost 
savings generated by the therapeutic innova-
tions of TKIs, as well as a useful tool which 
national and regional decision-makers could 
use to facilitate the allocative and manage-
ment decisions concerning the specific re-
sources for the treatment of newly diagnosed 
patients with Ph+ CML-CP.
reaching MMR with dasatinib; c) the market 
share absorbed by nilotinib. It is apparent that 
the initial molecular response is important 
not only for the patient’s quality of life, but 
also in terms of potential savings. In addition, 
the sensitivity analysis shows that the growth 
in the use of nilotinib, together with the use 
of generic imatinib, could allow an increase 
in benefits proportional to the number of pa-
tients actually treated. Finally, the analysis 
shows that, shouldn’t any TFR possibility 
exist, the reduction in spending would fall to 
€ 27.7 million at 4 years and € 43.9 million in 
the seventh year of the analysis (+ € 1.2 and 
+ € 10.5 million compared to the base case at 
4 and 7 years, respectively).
dIscussIon And conclusIons
In recent clinical practice it has been shown 
that, after an adequate period of treatment 
and in the presence of a very deep and sta-
ble molecular response, TKI treatment can 
be safely discontinued, with good chance of 
success [7,19].
Numerous studies showed the efficacy of 
nilotinib in the first-line treatment of Phila-
delphia chromosome-positive chronic mye-
loid leukemia adult patients [6,19,20]. Be-
sides these numerous advantages, obvious 
economic benefits can be identified, from the 
point of view of the National Health Servi-
ce. However, in the Italian context, no work 
included an economic evaluation of nilotinib 
with regard to the treatment strategy with the 
possibility of TFR.
This Budget Impact model showed that the 
use of nilotinib, in conjunction with the in-
troduction of the generic imatinib, represents 
on the one hand a significant response to the 
patient’s medical needs and, on the other, ge-
nerates at the same time an actual cost reduc-
tion, in the NHS’s perspective.
The probability to achieve TFR could allow 
for significant spending reductions over time, 
which is a great tool for the decision-maker 
in order to maintain high levels of effective-
ness and obtaining a decrease in the cost of 
therapies. The model estimated a net effect 
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Budget Impact analysis of the first-line treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)
AppendIx A
With the aim to model the natural history of 
adult patients with Ph+ CML-CP who un-
dergone to first-line treatment with nilotinib, 
imatinib or desatinib, it was necessary to 
make some assumptions. The clinical aspects 
of these assumptions have been reviewed and 
approved by Prof. Saglio.
1. Patients who remain in the TFR state for 
more than 1 year have a high probability 
to remain there also in the next years;
2. Patients who maintain MR4.5 and are not 
still ready, can go in the next years;
3. The right modeling of the switch state 
must be represented by the weighting of 
patients who switch to dasanitib or bo-
sutinib because of intolerance (2/3 of the 
patients) and patients who switch to po-
natinib because of resistance (1/3 of the 
patients);
4. Death due to disease is only possible du-
ring advance states of illness (AP/BC);
5. The distribution of patients who maintain 
MR4.5 from 1 to 4 years is linear;
6. Values range of some parameters were 
provided to implement the sensitivity 
analysis.
Table IA shows the transition probability de-
riving from the assumptions above.
Probability nilotinib [6,20] Imatinib [6] Dasatinib [6,8]
From start of treatment to MMR 0.73 0.54 0.68
From start of treatment to sub-optimal response/intolerance 0.24 0.42 0.29
From start of treatment to AP/BC 0.02 0.04 0.03
To stay in MMR 0.11 0.13 0.12
From MMR to MMR1* 0.89 0.87 0.88
From MMR1 to MMR 0.12 0.15 0.20
From MMR1 to MMR1.5* 0.88 0.85 0.80
From MMR1.5 to MMR 0.14 0.18 0.28
From MMR1.5 to MMR2* 0.86 0.82 0.72
From MMR2 to MMR 0.16 0.22 0.35
From MMR2 to MMR2.5* 0.83 0.78 0.64
From MMR2.5 to MMR 0.20 0.28 0.43
From MMR2.5 to MMR3* 0.80 0.71 0.57
From MMR3 to MMR 0.06 0.39 0.51
From MMR3 to MMR3.5* 0.94 0.61 0.49
From MMR3.5 to MMR 0.05 0.15 0.59
From MMR3.5 to MMRX* 0.94 0.85 0.41
From MMRX to MMR 0.06 0.24 0.00
To stay in MMRX 0.06 0.24 1.00
From MMRX to MMR0.5 0.88 0.52 0.00
From STOP0.5 to STOPX 0.48 0.44 0.00
From STOP0.5 to STOP1 0.52 0.56 0.00
To stay in STOP1 0.95 0.95 0.00
From STOP1 to STOPX 0.05 0.05 0.00
From MMR to Switch 0.003 0.003 0.003
From sub-optimal response/intolerance to Switch 1.00 1.00 1.00
From AP/BC to Allogeneic Transplantation 0.03 0.60 0.37
From AP/BC to death due to disease# 0.67 0.10 0.33
From AP/BC to Switch 0.3 0.3 0.30
To survive after transplantation 0.60 0.60 0.60
To die after transplantation 0.40 0.40 0.40
To survive after transplantation (years after the first) 0.95 0.95 0.95
To die after transplantation (years after the first) 0.05 0.05 0.05
Table Ia. Six-month transition probabilities
* Probabilities from MMR to MMR X were calculated assuming a linear trend of patients who leave from MMR and reach and maintain MMR4.5 from 4 years
# Probabilities of death from pivotal trials were converted into the ratio between deceased patients and deceased patients + patients in AP/BC state as 
estimated by pivotal trials (because of the assumption that only patients in advance states of illness can die)
